Clinical Trial Update: Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating Besponsa (Inotuzumab ozogamicin) for B-cell acute lymphoblastic leukemia with positive minimal residual disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• Besponsa (inotuzumab ozogamicin)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING